JTCS Email Content Delivery
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Willem Flameng
Bart Meuris
Paul Herijgers
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Flameng, W.
Right arrow Articles by Herregods, M.-C.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Flameng, W.
Right arrow Articles by Herregods, M.-C.
Related Collections
Right arrow Valve disease

J Thorac Cardiovasc Surg 2008;135:274-282
© 2008 The American Association for Thoracic Surgery

Surgery for Acquired Cardiovascular Disease

Durability of mitral valve repair in Barlow disease versus fibroelastic deficiency

Willem Flameng, MD, PhDa,*, Bart Meuris, MD, PhDa, Paul Herijgers, MD, PhDa, Marie-Christine Herregods, MD, PhDb

a Cardiac Surgery, Department of Cardiovascular Diseases, Katholieke Universiteit Leuven, Leuven, Belgium
b Cardiology, Department of Cardiovascular Diseases, Katholieke Universiteit Leuven, Leuven, Belgium

Received for publication February 2, 2007; revisions received June 12, 2007; accepted for publication June 14, 2007.

* Address for reprints: Willem Flameng, MD, PhD, Cardiac Surgery, University Clinic Gasthuisberg, Herestraat 49, B-3000 Leuven, Belgium. (Email: willem.flameng{at}med.kuleuven.ac.be).

Objective: Durability assessment of mitral valve repair for degenerative valve incompetence is limited to reoperation as a primary indicator and valve-related risk factors for late death as a secondary indicator. We assessed serial echocardiographic follow-up of valve function as an indicator of the durability of mitral valve repair.

Methods and Results: In 348 patients having undergone mitral valve repair for degenerative valve incompetence, clinical outcome was excellent: 10 years after repair, survival was 80.1% and freedom from reoperation 94.4%. However, freedom from mitral regurgitation (>2/4), 98.7% at 1 month, decreased to 82.2% at 5 years and 64.9% at 10 years. The linearized recurrence rate of mitral regurgitation (>2/4) was 3.2% per year. Recurrence rate was higher in patients with Barlow disease (6.0%) and lower in those with fibroelastic deficiency (2.6%) (P = .01). Performing chordal shortening, the nonuse of sliding plasty and the nonuse of an annuloplasty ring were determined to be factors predicting recurrence of mitral regurgitation. In reconstructions avoiding these risk factors, recurrence rate decreased to 2.4%. There was no difference between Barlow disease and fibroelastic deficiency: 2.9% versus 2.2% (P > .05). Recurrent regurgitation is characterized by leaflet prolapse, thickening, and calcification.

Conclusion: When optimal surgical techniques are used, the residual recurrence rate of mitral valve regurgitation remains between 2% and 3% per year and is related to progressive degeneration of the chordae and the leaflets. Long-term results of mitral valve repair in Barlow disease are essentially the same as in fibroelastic deficiency.

Abbreviations and Acronyms NYHA = New York Heart Association; SAM = systolic anterior motion






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 2008 by The American Association for Thoracic Surgery.